查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1607980

血红蛋白疾病市场：按适应症、治疗、诊断和最终用户分类 - 全球预测 2025-2030

Hemoglobinopathies Market by Indication (Sickle Cell Disease, Thalassemia), Treatment (Blood Transfusion, Bone Marrow & Stem Cell Transplant, Chemotherapy), Diagnosis, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年血红素病市场价值为26.3亿美元，预计到2024年将达到27.9亿美元，复合年增长率为33.02%，到2030年将达到194.6亿美元。

镰状细胞疾病和地中海贫血等血红蛋白疾病是影响血红蛋白（红血球中的一种蛋白质）的遗传性疾病。血红蛋白病市场范围包括诊断、治疗和支持护理，为患者、医疗保健提供者和研究人员提供服务。与血红蛋白疾病相关的高发病率和死亡率强调了解决这些疾病的必要性，需要早期诊断、有效管理和定期监测。治疗范围从基因检测和输血通讯协定到创新的基因和干细胞治疗。最终用途范围主要包括医院、专科诊所和专门研究遗传疾病的研究机构。

主要市场统计
基准年[2023] 26.3亿美元
预测年份 [2024] 27.9亿美元
预测年份 [2030] 194.6亿美元
复合年增长率（%） 33.02%

目前，市场成长的推动因素包括基因研究的进步、患者和医疗保健专业人员意识的提高以及新疗法的不断扩大。值得注意的机会在于开发具有成本效益的基因测试和先进的治疗解决方案，例如基于 CRISPR 的基因编辑和小分子药物。公司还应该探索个人化医疗方法和伙伴关係，旨在改善患者治疗结果并降低医疗成本。然而，成长面临着高昂的治疗成本、低收入地区获得医疗保健的机会有限以及遗传和临床研究的复杂性等挑战。监管障碍和大规模临床试验的需要也减缓了新治疗方法的开发。

为了克服这些挑战，公司应该专注于基因治疗和照护现场的创新。与生技公司和学术机构建立有效的伙伴关係可以提供合作研究机会并提高研发能力。还可以扩大患者支持计划和提高认识倡议，以改善有关血红蛋白病的教育。由于市场是动态的，并且越来越多地转向个人化医疗和精准医疗解决方案，市场参与者必须适应这些趋势并投资于突破性研究，以获得并保持竞争优势至关重要。

市场动态：针对快速发展的血红蛋白病市场揭示的关键市场洞察

血红蛋白病市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 常见罕见血液相关疾病的盛行率不断上升
    • 寻求血红蛋白疾病治疗的患者数量增加
    • 新型血红蛋白病治疗药物的监管核准增加
  • 市场限制因素
    • 与血红蛋白病治疗相关的高成本
  • 市场机会
    • 治疗血红蛋白疾病的持续研究和开发活动
    • 治疗血红蛋白疾病的新治疗方法和诊断方法的可用性
  • 市场挑战
    • 对血红素病治疗缺乏认识

波特的五力：驾驭血红素病市场的策略工具

波特的五力架构是了解血红素病市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解血红素病市场的外部影响

外部宏观环境因素在塑造血红蛋白病市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解血红素病市场的竞争状况

血红蛋白病市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来发现自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵血红素病市场供应商的绩效评估

FPNV 定位矩阵是评估血红素病市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製血红蛋白病市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对血红蛋白病市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 常见罕见血液相关疾病的盛行率增加
      • 寻求血红蛋白疾病治疗的患者数量增加
      • 新治疗方法的监管核准增加
    • 抑制因素
      • 与血红蛋白病治疗相关的高成本
    • 机会
      • 正在进行的治疗血红蛋白病的研究和开发活动
      • 治疗血红蛋白疾病的新药物疗法和诊断方法的可用性
    • 任务
      • 对血红素病治疗方法缺乏认识
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 血红素病市场（依适应症）

  • 镰状细胞性贫血症
  • 地中海型贫血
    • α地中海贫血
    • β地中海型贫血

第七章 依治疗分類的血红素疾病市场

  • 输血
  • 骨髓和干细胞移植
  • 化疗
  • 治疗疗法
  • 基因治疗
  • 羟基尿素
  • 铁螯合疗法

第八章依诊断分类的血红素疾病市场

  • 基因检测
  • 血红素等电聚焦 (Hb IEF)
  • 血红素溶解度测试
  • 高效液相层析测定血红素
  • 血红素电泳 (Hb ELP)
  • 定期测量红血球计数 (RBC)

第 9 章 血红素病市场：按最终用户

  • 诊所
  • 诊断实验室
  • 医院

第10章北美和南美的血红素病市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太血红素病市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲/中东/非洲血红素病市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Alnylam Pharmaceuticals, Inc.
  • Bio-Rad Laboratories Inc.
  • Biogen Inc.
  • Bluebird Bio, Inc.
  • Bristol Myers Squibb
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Emmaus Life Sciences Inc.
  • Gamida Cell Ltd.
  • Genetix Biotech Asia Pvt. Ltd
  • Laboratory Corporation
  • Medunik USA Inc.
  • Merck & Co. Inc.
  • Nexcelom Bioscience LLC
  • Novartis AG
  • PerkinElmer Inc.
  • Pfizer, Inc.
  • Prolong Pharmaceuticals, LLC
  • Regenacy Pharmaceuticals, Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Sebia
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd
  • Sysmex Corporation
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-C002B1C994F1

The Hemoglobinopathies Market was valued at USD 2.63 billion in 2023, expected to reach USD 2.79 billion in 2024, and is projected to grow at a CAGR of 33.02%, to USD 19.46 billion by 2030.

Hemoglobinopathies, such as sickle cell disease and thalassemia, are genetic disorders affecting hemoglobin, the protein in red blood cells. The scope of the market for hemoglobinopathies encompasses diagnostics, therapeutics, and supportive care, serving patients, healthcare providers, and researchers. The necessity of addressing hemoglobinopathies is underscored by the considerable morbidity and mortality rates associated with these conditions, necessitating early diagnosis, effective management, and periodic monitoring. Applications range from genetic testing and blood transfusion protocols to innovative gene therapies and stem cell treatments. The end-use scope primarily involves hospitals, specialty clinics, and research institutes focused on genetic disorders.

KEY MARKET STATISTICS
Base Year [2023] USD 2.63 billion
Estimated Year [2024] USD 2.79 billion
Forecast Year [2030] USD 19.46 billion
CAGR (%) 33.02%

Currently, market growth is being fueled by advances in genetic research, rising awareness among patients and healthcare professionals, and the expanding pipeline of novel therapies. Notable opportunities lie in developing cost-effective genetic tests and advanced therapeutic solutions such as CRISPR-based gene editing and small molecule drugs. Companies should also explore personalized medicine approaches and partnerships aimed at improving patient outcomes and reducing healthcare costs. However, growth is challenged by high treatment costs, limited access to healthcare in low-income regions, and the complexities involved in genetic and clinical research. Regulatory hurdles and the need for extensive clinical trials can also slow the development of new treatments.

To overcome these challenges, companies should focus on innovations in gene therapy and point-of-care diagnostics. Developing effective partnerships with biotechnological firms and academic institutions can provide collaborative research opportunities and enhance R&D capabilities. There is also scope for expanding patient support programs and awareness initiatives to improve education around hemoglobinopathies. The market is dynamic, with a shift towards personalized and precision medicine solutions, making it imperative for market players to adapt and invest in groundbreaking research that aligns with these trends to capture and sustain a competitive edge.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hemoglobinopathies Market

The Hemoglobinopathies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of common rare blood-related diseases
    • Rising numbers of patients seeking hemoglobinopathies treatments
    • Increasing approvals from the regulatory bodies for novel hemoglobinopathies therapies
  • Market Restraints
    • High cost associated with hemoglobinopathies treatment
  • Market Opportunities
    • Ongoing R&D activities for the hemoglobinopathies treatment
    • Availability of new medicinal therapies and diagnostic methods for hemoglobinopathies treatment
  • Market Challenges
    • Lack of awareness about hemoglobinopathies therapies

Porter's Five Forces: A Strategic Tool for Navigating the Hemoglobinopathies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hemoglobinopathies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hemoglobinopathies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hemoglobinopathies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hemoglobinopathies Market

A detailed market share analysis in the Hemoglobinopathies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hemoglobinopathies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hemoglobinopathies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hemoglobinopathies Market

A strategic analysis of the Hemoglobinopathies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hemoglobinopathies Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alnylam Pharmaceuticals, Inc., Bio-Rad Laboratories Inc., Biogen Inc., Bluebird Bio, Inc., Bristol Myers Squibb, CRISPR Therapeutics AG, Danaher Corporation, Emmaus Life Sciences Inc., Gamida Cell Ltd., Genetix Biotech Asia Pvt. Ltd, Laboratory Corporation, Medunik USA Inc., Merck & Co. Inc., Nexcelom Bioscience LLC, Novartis AG, PerkinElmer Inc., Pfizer, Inc., Prolong Pharmaceuticals, LLC, Regenacy Pharmaceuticals, Inc., Sangamo Therapeutics, Inc., Sanofi S.A., Sebia, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Sysmex Corporation, and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Hemoglobinopathies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Sickle Cell Disease and Thalassemia. The Thalassemia is further studied across Alpha Thalassemia and Beta thalassemia.
  • Based on Treatment, market is studied across Blood Transfusion, Bone Marrow & Stem Cell Transplant, Chemotherapy, Curative Therapy, Gene Therapy, Hydroxyurea, and Iron Chelation Therapy.
  • Based on Diagnosis, market is studied across Genetic Testing, Haemoglobin Isoelectric Focusing (Hb IEF), Haemoglobin Solubility Test, Hemoglobin by High Performance Liquid Chromatography, Hemoglobin electrophoresis (Hb ELP), and Routine Red Blood Cell (RBC) Count.
  • Based on End-User, market is studied across Clinics, Diagnostic Laboratories, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of common rare blood-related diseases
      • 5.1.1.2. Rising numbers of patients seeking hemoglobinopathies treatments
      • 5.1.1.3. Increasing approvals from the regulatory bodies for novel hemoglobinopathies therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with hemoglobinopathies treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D activities for the hemoglobinopathies treatment
      • 5.1.3.2. Availability of new medicinal therapies and diagnostic methods for hemoglobinopathies treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness about hemoglobinopathies therapies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hemoglobinopathies Market, by Indication

  • 6.1. Introduction
  • 6.2. Sickle Cell Disease
  • 6.3. Thalassemia
    • 6.3.1. Alpha Thalassemia
    • 6.3.2. Beta thalassemia

7. Hemoglobinopathies Market, by Treatment

  • 7.1. Introduction
  • 7.2. Blood Transfusion
  • 7.3. Bone Marrow & Stem Cell Transplant
  • 7.4. Chemotherapy
  • 7.5. Curative Therapy
  • 7.6. Gene Therapy
  • 7.7. Hydroxyurea
  • 7.8. Iron Chelation Therapy

8. Hemoglobinopathies Market, by Diagnosis

  • 8.1. Introduction
  • 8.2. Genetic Testing
  • 8.3. Haemoglobin Isoelectric Focusing (Hb IEF)
  • 8.4. Haemoglobin Solubility Test
  • 8.5. Hemoglobin by High Performance Liquid Chromatography
  • 8.6. Hemoglobin electrophoresis (Hb ELP)
  • 8.7. Routine Red Blood Cell (RBC) Count

9. Hemoglobinopathies Market, by End-User

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Diagnostic Laboratories
  • 9.4. Hospitals

10. Americas Hemoglobinopathies Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Hemoglobinopathies Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Hemoglobinopathies Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alnylam Pharmaceuticals, Inc.
  • 3. Bio-Rad Laboratories Inc.
  • 4. Biogen Inc.
  • 5. Bluebird Bio, Inc.
  • 6. Bristol Myers Squibb
  • 7. CRISPR Therapeutics AG
  • 8. Danaher Corporation
  • 9. Emmaus Life Sciences Inc.
  • 10. Gamida Cell Ltd.
  • 11. Genetix Biotech Asia Pvt. Ltd
  • 12. Laboratory Corporation
  • 13. Medunik USA Inc.
  • 14. Merck & Co. Inc.
  • 15. Nexcelom Bioscience LLC
  • 16. Novartis AG
  • 17. PerkinElmer Inc.
  • 18. Pfizer, Inc.
  • 19. Prolong Pharmaceuticals, LLC
  • 20. Regenacy Pharmaceuticals, Inc.
  • 21. Sangamo Therapeutics, Inc.
  • 22. Sanofi S.A.
  • 23. Sebia
  • 24. Shenzhen Mindray Bio-Medical Electronics Co., Ltd
  • 25. Sysmex Corporation
  • 26. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. HEMOGLOBINOPATHIES MARKET RESEARCH PROCESS
  • FIGURE 2. HEMOGLOBINOPATHIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HEMOGLOBINOPATHIES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HEMOGLOBINOPATHIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEMOGLOBINOPATHIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEMOGLOBINOPATHIES MARKET DYNAMICS
  • TABLE 7. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY SICKLE CELL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY ALPHA THALASSEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY BETA THALASSEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY BONE MARROW & STEM CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY CURATIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY HYDROXYUREA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY IRON CHELATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY HAEMOGLOBIN ISOELECTRIC FOCUSING (HB IEF), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY HAEMOGLOBIN SOLUBILITY TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY HEMOGLOBIN BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS (HB ELP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY ROUTINE RED BLOOD CELL (RBC) COUNT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 241. HEMOGLOBINOPATHIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 242. HEMOGLOBINOPATHIES MARKET, FPNV POSITIONING MATRIX, 2023